Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATOS Atossa Genetics

Pre-Mkt 05-18 06:04:34 EDT

4.85

-0.30

-5.83%

High5.11	Low4.85	Vol46.18K
Open5.11	D1 Closing5.15	Amplitude5.05%
Mkt Cap41.77M	Tradable Cap41.74M	Total Shares8.61M
T/O227.04K	T/O Rate0.54%	Tradable Shares8.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATOS","market":"US","secType":"STK","nameCN":"Atossa Genetics","latestPrice":4.85,"timestamp":1778875200000,"preClose":5.15,"halted":0,"volume":46175,"delay":0,"changeRate":-0.05825242718446615,"floatShares":8606660,"shares":8611428,"eps":-4.37,"marketStatus":"Pre-Mkt","change":-0.3,"latestTime":"05-18 06:04:34 EDT","open":5.11,"high":5.11,"low":4.85,"amount":227036.499955,"amplitude":0.050485,"askPrice":5.26,"askSize":100,"bidPrice":4.31,"bidSize":38,"shortable":3,"etf":0,"ttmEps":-4.37,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779111000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1352350800000,"exchange":"NASDAQ","adjPreClose":4.85,"postHourTrading":{"tag":"盘后","latestPrice":4.94,"preClose":4.85,"latestTime":"19:00 EDT","volume":113,"amount":557.2891,"timestamp":1778886043851,"change":0.09,"changeRate":0.018557,"amplitude":0.018557},"volumeRatio":1.2080536909591997,"impliedVol":0.9097,"impliedVolPercentile":0.4257},"requestUrl":"/m/hq/s/ATOS","defaultTab":"news","newsList":[{"id":"2633944468","title":"Atossa Therapeutics Inc  expected to post a loss of $1.03 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633944468","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633944468?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:42","pubTimestamp":1778254928,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc  expected to post a loss of $1.03 a share - Earnings Preview Atossa Therapeutics Inc ATOS.OQ ATOS.O is expected to  show no change in quarterly revenue when it reports  results","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1X6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633459412","title":"Atossa Therapeutics Q1 net loss widens on higher legal and R&D expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459412","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633459412?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:53","pubTimestamp":1778244783,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Q1 net loss widens on higher legal and R&D expensesOverviewU.S. biopharma firm's Q1 net loss widened yr/yr on higher R&D and legal expensesCompany secured FDA Orphan Drug and Rare ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL1N41L0JB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633459918","title":"Atossa presents preclinical (Z)-endoxifen data in Duchenne muscular dystrophy mouse models","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459918","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633459918?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:46","pubTimestamp":1778244391,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics highlighted preclinical study results for -endoxifen in Duchenne muscular dystrophy that were already presented March 11, 2026 at MDA Clinical & Scientific Conference.Data indicated -endoxifen improved muscle function and body composition in dystrophic mouse models, supporting a move toward clinical testing.FDA granted Orphan Drug designation for -endoxifen in Duchenne muscular dystrophy in January 2026, strengthening regulatory positioning for a potential rare-disease development path.FDA also granted Rare Pediatric Disease designation for -endoxifen in McCune-Albright Syndrome in early May 2026, creating potential eligibility for a Priority Review Voucher upon approval of a qualifying marketing application.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL5rq01f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145964","title":"Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145964?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:45","pubTimestamp":1778244300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUAWKPK5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633459644","title":"Atossa Therapeutics Q1 Operating Expenses USD 9.87 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459644","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633459644?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:45","pubTimestamp":1778244300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nPLX325B7E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633456723","title":"Atossa Therapeutics Q1 FY26 net loss widens 61.07% to $9.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633456723","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633456723?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:32","pubTimestamp":1778243538,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics posted a net loss of USD 9.6 million for the quarter ended March 31, 2026, while reporting no revenue.Operating expenses climbed 33.78% to USD 9.9 million, led by a 15% rise in R&D spending to USD 4.78 million.G&A costs rose 56% to USD 5.09 million, driven by higher legal fees tied to patent litigation and intellectual property matters.Cash and cash equivalents totaled USD 31.7 million at quarter-end as net cash used in operating activities widened to USD 9.58 million; management said existing resources likely will be insufficient to fund planned operations for the next 12 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief v","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL2PbXNd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633120455","title":"Atossa Therapeutics shareholders approve reverse stock split authorization","url":"https://stock-news.laohu8.com/highlight/detail?id=2633120455","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633120455?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:02","pubTimestamp":1778241779,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics held its annual stockholder meeting on May 7, 2026.Stockholders backed an amendment to certificate of incorporation authorizing board to implement a reverse stock split, if it determines one is necessary or appropriate, at a ratio ranging from 2-for-1 to 20-for-1.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL7rZMFx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633448133","title":"Atossa says Phase 2 KARISMA trial shows Endoxifen cuts mammographic breast density 19.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633448133","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633448133?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:33","pubTimestamp":1778070835,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics flagged peer-reviewed publication of results from KARISMA Endoxifen trial in Journal of National Cancer Institute, with results already presented via publication.Phase 2 study in healthy premenopausal women showed low-dose oral endoxifen reduced mammographic breast density versus placebo, supporting its positioning as potential breast cancer risk-reduction option.Lower dose delivered meaningful effect with tolerability broadly similar to placebo, while higher dose drove more treatment-related discontinuations, shaping dose selection for future development.Program rationale centers on bypassing tamoxifen metabolism variability by dosing active metabolite directly, aiming to improve predictability and long-term acceptability in prevention setting.Next step remains clinical work to determine whether endoxifen lowers breast cancer incidence in higher-risk women, beyond biomarker changes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL2lhspQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633613311","title":"Atossa Therapeutics Announces Publication of Karisma Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women","url":"https://stock-news.laohu8.com/highlight/detail?id=2633613311","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633613311?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:30","pubTimestamp":1778070645,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nFWN41J0TW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632395313","title":"BRIEF-Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation For (Z)-Endoxifen For Mccune-Albright Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2632395313","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632395313?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:34","pubTimestamp":1777898068,"startTime":"0","endTime":"0","summary":"BRIEF-Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation For (Z)-Endoxifen For Mccune-Albright SyndromeMay 4 (Reuters) - Atossa Therapeutics Inc ATOS.O:ATOSSA THERAPEUTICS RECEIVES FD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA1QGBCC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632953990","title":"Atossa says FDA grants rare pediatric disease designation for (Z)-endoxifen in MAS","url":"https://stock-news.laohu8.com/highlight/detail?id=2632953990","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632953990?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:32","pubTimestamp":1777897939,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics received FDA Rare Pediatric Disease designation for -endoxifen to treat McCune-Albright Syndrome in females.Designation could make company eligible for a Priority Review Voucher if a qualifying marketing application is approved.Disclosed Priority Review Voucher sales over past 18-24 months ranged from about $100 million to $205 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on May 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL1djTrs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627739218","title":"Atossa Therapeutics - Co, Intas Pharmaceuticals, Jina Pharmaceuticals Agree Not to Challenge Specified Endoxifen-Related Patents - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627739218","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627739218?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:33","pubTimestamp":1776342828,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Z0UP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627218736","title":"Atossa Therapeutics - Parties Agree to Seek Termination of Ptab Proceedings - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627218736","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627218736?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:33","pubTimestamp":1776342828,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Z0UP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627218053","title":"Atossa Therapeutics - Two Endoxifen Patents Expected to Remain Issued and Enforceable - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627218053","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627218053?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:33","pubTimestamp":1776342828,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Z0UP:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627187802","title":"Atossa Therapeutics - on April 13, Co Entered Settlement Agreement to Resolve Endoxifen Patent Disputes - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627187802","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627187802?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:33","pubTimestamp":1776342828,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Z0UP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627218268","title":"Atossa settles Endoxifen patent dispute with Intas, Jina Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2627218268","media":"Reuters","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627218268?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:31","pubTimestamp":1776342704,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics entered settlement agreement April 13, 2026 with Intas Pharmaceuticals, targeting resolution of Endoxifen patent disputes.Deal calls for termination of pending U.S. Patent Trial and Appeal Board proceedings challenging two Atossa patents.Settlement includes mutual non-challenge covenants covering specified Endoxifen-related patents and applications, subject to limited exceptions.Agreement preserves Atossa ability to develop and commercialize Z-endoxifen base in oncology, endocrine dysfunction disorders, muscular dystrophy-related diseases.Upon PTAB termination, Atossa expects patents 11,261,151 and 12,071,391 to remain issued and enforceable against other third parties.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL737kZh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622847966","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622847966?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:00","pubTimestamp":1774605600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·SBC Med Grp Hld                                  4Q       .12       BMO. ·INmune Bio Inc                                  4Q      (.26)  4:05 PM. ·Banzai Intl Cl A                                4Q      (.59)      AMC. ·FactSet Res Sys                                  2Q      4.38   6:00 AM. ·McCormick & Co                                 1Q       .60   6:30 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FDS","KOPN","BNZI","NCNO","AUTL","BHST","LGN","NEOG","CCL","MKC","BTBT","NKE","BCAX","AIRO","MKC.V","BEEM","DMAC","INMB","KYTX","NKLR","PHR","PLAY","AEHR","LW","KEEL","LNN","PENG","MSM","AYI","CALM","CAG","CRDL","INV","ATOS","BYND","BIRD","AURA","HUMA","MSLE","NGEN","APOG","DEFT","RNXT","FC","IMNN","NMRA","JILL","ANGO","PRGS","AIRJ","BITF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622985458","title":"Atossa Therapeutics : H.c. Wainwright Adjusts Target Price to $25 to Reflect 1-for-15 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2622985458","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622985458?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:25","pubTimestamp":1774524332,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E0ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622000835","title":"Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000835","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622000835?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:30","pubTimestamp":1774474200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUA3M5CNY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622007795","title":"Atossa Therapeutics FY2025 operating loss widens 34% to $(37) million; loss per share widens to $(4.04)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622007795","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622007795?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:22","pubTimestamp":1774473775,"startTime":"0","endTime":"0","summary":"Atossa published an annual report on Form 10-K for the year ended Dec. 31, 2025, reporting no revenue.Net loss was USD 34.8 million, and net loss per share was USD 4.04.Research and development expense rose 50% to USD 21.2 million, driven by higher spending on -endoxifen trials and increased drug development costs.General and administrative expense increased 18% to USD 16.0 million, primarily due to higher legal fees tied to ongoing litigation and patent defense.Cash and cash equivalents were USD 41.3 million at year-end, and management said existing resources are expected to fund planned operations for the next 12 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to gen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL1ZxbWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atossatherapeutics.com;investors.atossatherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1339},{"period":"1month","weight":-0.1551},{"period":"3month","weight":0.1548},{"period":"6month","weight":-0.5958},{"period":"1year","weight":-0.6719},{"period":"ytd","weight":-0.452}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.269844},{"month":2,"riseRate":0.5,"avgChangeRate":0.058135},{"month":3,"riseRate":0.428571,"avgChangeRate":0.091975},{"month":4,"riseRate":0.357143,"avgChangeRate":-0.038564},{"month":5,"riseRate":0.357143,"avgChangeRate":-0.020344},{"month":6,"riseRate":0.615385,"avgChangeRate":0.128869},{"month":7,"riseRate":0.230769,"avgChangeRate":-0.109234},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.058495},{"month":9,"riseRate":0.307692,"avgChangeRate":-0.023021},{"month":10,"riseRate":0.153846,"avgChangeRate":-0.183809},{"month":11,"riseRate":0.307692,"avgChangeRate":-0.054625},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.125403}],"exchange":"NASDAQ","name":"Atossa Genetics","nameEN":"Atossa Genetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Atossa Genetics,ATOS,Atossa Genetics股票,Atossa Genetics股票老虎,Atossa Genetics股票老虎国际,Atossa Genetics行情,Atossa Genetics股票行情,Atossa Genetics股价,Atossa Genetics股市,Atossa Genetics股票价格,Atossa Genetics股票交易,Atossa Genetics股票购买,Atossa Genetics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction